Welcome to our dedicated page for Psyence Biomedical Ltd. news (Ticker: PBM), a resource for investors and traders seeking the latest updates and insights on Psyence Biomedical Ltd. stock.
Psyence Biomedical Ltd. (PBM) pioneers natural psilocybin therapies for mental health challenges in palliative care through rigorous clinical research. This dedicated news hub provides investors and medical professionals with essential updates on therapeutic developments shaping the future of psychedelic medicine.
Access real-time announcements about clinical trial milestones, manufacturing advancements, and strategic partnerships. Our curated collection includes press releases covering regulatory progress, research publications, and operational updates from the company’s EU GMP-compliant production facility.
Key content categories include phase trial results for Adjustment Disorder therapies, psilocybin cultivation innovations, and collaborative research initiatives with leading clinical organizations. All materials maintain strict compliance with pharmaceutical disclosure standards and financial reporting requirements.
Bookmark this page for direct access to Psyence Biomedical’s verified announcements. Stay informed about groundbreaking developments in psychedelic-assisted psychotherapy and evidence-based treatment protocols through our comprehensive news repository.
Psyence BioMed (Nasdaq: PBM) announced it secured a sustainable, high‑potency supply of iboga bark via partner PsyLabs to support clinical development of pharmaceutical‑grade ibogaine for substance use disorders and research markets.
The company received an initial 50 kg shipment being processed into ibogaine HCl and Total Alkaloid Extracts, with PsyLabs’ material described as GMP‑compliant. The collaboration emphasizes ethical sourcing, sustainability, and benefit‑sharing with source communities to build a vertically integrated supply chain for clinical research.
Psyence BioMed (Nasdaq: PBM) announced a strategic investment in PsyLabs to establish ibogaine operations and manufacturing in Africa, with PsyLabs operating an EU GMP-grade facility in Southern Africa.
The move gives PBM vertical integration across cultivation, extraction, and purification, positioning the company with traceable supply from the ibogaine source and control of quality for research and commercial development.
The release cites rising global momentum for ibogaine research, including a $50 million Texas research allocation in 2025 and recent pharmaceutical M&A activity around ibogaine analogs.
Psyence BioMed (Nasdaq: PBM) reported multiple patients have been dosed in its Phase IIb study of nature-derived psilocybin plus psychotherapy for Adjustment Disorder in palliative care.
The multi-site, double-blind, placebo-controlled trial is designed to enroll 87 patients across Australia with doses of 10 mg, 25 mg or a low-dose comparator of 1 mg. Patients have been dosed at the Empax Center in Perth and the Mind Medicine Australia Clinic in Melbourne, and Paratus Clinical Research has been activated to expand to a third enrolling site. Topline results are anticipated by year-end 2026.
Psyence BioMed (Nasdaq: PBM) made a USD 3,500,000 follow-on investment in PsyLabs on August 15, 2025, after an earlier USD 500,000 investment in April 2025. The investment secures PsyLabs as a primary supplier of GMP‑grade psilocybin and ibogaine for Psyence BioMed’s clinical programs and aims to ensure an ethical, sustainable supply chain for the company’s nature-derived psychedelic pipeline.
The partnership highlights Psyence BioMed’s strategic focus on integrated supply from Southern Africa and notes certain executives provide consulting services to PsyLabs and collectively own less than 5% of PsyLabs.
Psyence BioMed (NASDAQ:PBM), a biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies for mental health, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The conference will be held at the Lotte New York Palace Hotel in New York City and virtually.
CEO Dr. Neil Maresky will present the company's business strategy and pipeline. The virtual presentation will be available on-demand starting September 5, 2025, at 7:00 AM EST. Additionally, the company will host a separate webinar featuring its Scientific Advisory Board on September 16, 2025, at 12:00 PM EST to discuss ongoing clinical development programs and strategic initiatives.
[]Psyence BioMed (NASDAQ: PBM) provided a comprehensive corporate update highlighting significant progress across multiple fronts. The company reported a strong cash position of $11.4 million with no outstanding debt and successfully regained Nasdaq compliance following a 1-for-7.97 reverse stock split.
Key developments include protocol amendments to expand patient eligibility in clinical trials, activation of three clinical sites, and advancement of their Alcohol Use Disorder (AUD) study. The company strengthened its strategic alliance with PsyLabs, achieving GMP-aligned Ibogaine Total Alkaloid extract production. PBM is positioning itself in the projected $3.3 billion psychedelics market by 2031, focusing on developing naturally derived psychedelic therapies for mental health conditions.
Psyence BioMed (Nasdaq: PBM) announced that its strategic partner, PsyLabs, has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract meeting food-grade consumption safety standards. This achievement follows PBM's strategic equity investments in PsyLabs during 2024 and 2025.
The breakthrough represents a significant milestone in producing high-quality psychedelic APIs, with PsyLabs' extract passing third-party laboratory verification. The company is expanding its chemistry production facilities to meet growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs derived from Iboga and Mushrooms.
The products will be available to licensed research institutions and developers globally, ensuring reliable and ethical sourcing of psychedelic compounds.
Psyence BioMed (NASDAQ: PBM) has finalized a service agreement with Southern Star Research, an award-winning Australian CRO, to manage their Phase IIb clinical trial investigating psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients. The double-blind, placebo-controlled study will enroll 87 participants to assess three doses of psilocybin combined with psychotherapy.
Southern Star Research, recipient of the 2024 Asia-Pacific Competitive Strategy Leadership Award, brings 14 years of expertise in oncology and mental health trials. They will oversee full trial management, including clinical monitoring, project management, and data handling. The study addresses a significant unmet need, as Adjustment Disorder affects up to 19% of cancer patients.
Additionally, FDA Commissioner Marty Makary has expressed support for psychedelic medicine, promising an "expeditious and rapid review" of clinical data from psychedelic trials under the Trump administration.
FAQ
What is the current stock price of Psyence Biomedical Ltd. (PBM)?
What is the market cap of Psyence Biomedical Ltd. (PBM)?
